Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press release (2)

2025 Q3 Earnings Call
press releaseinvestor
eXoZymes to host third quarter 2025 update on Thursday November 13, 2025, at 5PM ESTNovember 10, 2025
CCO Damien Perriman and co-founder and VP of Development, Dr. Paul Opgenorth.
press releasescienceperriman
Driving the cell-free revolution: eXoZymes leaders join BioMADE Leadership & Technical CommitteesSeptember 30, 2025
eXoZymes provides second quarter 2025 update at 5PM EST today
press releaseinvestor
eXoZymes provides second quarter 2025 update at 5PM EST todayAugust 12, 2025
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM EST
press releaseinvestor
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM ESTAugust 7, 2025
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscienceperriman
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
heltzenpress releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
Dr. Paul Opgenorth
press releaseinvestornutraceuticalsmedicinescience
eXoZymes selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturingJune 26, 2025
Michael Heltzen & Erum Azeez Khan
heltzenpress releaseinvestorpress clippingsvideopodcast
Podcast: eXoZymes highlights scalable biomanufacturing platform and first spinout, NCTx, on 'Grow Everything'May 16, 2025
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST today
press releaseinvestor
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST todayMay 12, 2025
eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM EST
press releaseinvestor
eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM ESTMay 7, 2025
Previous page
Page 2 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark